Treventis Corporation focuses on treating and preventing protein misfolding diseases, which are a significant unmet medical need. The company leverages a combination of unique computational models and deep wetware expertise to develop innovative drug programs aimed at stopping the misfolding of proteins. This approach has the potential to create disease-modifying therapies for a variety of conditions. Treventis' lead program is centered on developing a differentiated collection of narrow and broad-spectrum anti-misfolding small molecules, particularly targeting tauopathies such as 3R, 4R, familial mutations, and mixed forms. The company's breakthrough CCM technology enables researchers to model misfolded protein structures for the first time, providing powerful new ways to discover therapies for targeted neurodegenerative disorders. Treventis operates in the biopharmaceutical market, serving clients in the healthcare and medical research sectors. The business model is based on the development and commercialization of proprietary drug candidates, generating revenue through partnerships, licensing agreements, and potential future sales of approved therapies.

Keywords: protein misfolding, drug development, computational models, wetware expertise, tauopathies, neurodegenerative disorders, CCM technology, biopharmaceutical, healthcare, medical research.